EP300 and neoplasm: Our finding that p300/CBP-specific HATis cause significant killing of MCPyV+ MCC cells is exciting because, in the in vivo setting, tumor antigens released by dying MCC cells could be engulfed by antigen-presenting cells (APCs) to activate T cells, which can then kill more tumor cells and amplify the tumoricidal effect [87].